Mon. Jun 14th, 2021

Global Folate Deficiency Anemia Drug Market–Industry Trends and Forecast to 2027” New Research Report Added to database. The report width Of pages : 350  Figures: 60 And Tables: 220 in it.

Global Folate Deficiency Anemia Drug Market Statistical Overview Report 2020 gives an outstanding tool for market Survey, openings, and Vital key and strategic basic leadership. This report perceives that in this quickly advancing and competitive scenario, up-coming data on the basis of research execution and settle on basic choices for development and benefit. It gives data on Global Folate Deficiency Anemia Drug Market trends and advancements and sheds light on various sectors, limitations and advancements, and on the evolving structure of the market.

Global folate deficiency anemia drug market is rising gradually with a substantial CAGR in the forecast period of 2019-2026. Government policies and initiatives to offer a fund to many research institute and pharmaceuticals companies for developing novel therapy and emergence of drugs used in the treatment of Crohn’s disease, celiac disease, certain types of cancer and kidney problem that required dialysis as these can cause folate deficiencies are the key factors for the growth of this market

Download Exclusive Sample Report (350 Pages PDF with All Related Graphs & Charts) @

Key Market Players:

Few of the major competitors currently working in the global folate deficiency anemia drug market are GlaxoSmithKline plc, Eli Lilly and Company, Merck KGaA, bluebird bio, Inc, Biocon, GlycoMimetics, Regen BioPharma Inc, Bayer AG, Acceleron Pharma, Inc., Johnson & Johnson Services, Inc., F. Hoffmann-La Roche Ltd, Pfizer Inc, Merck & Co., Inc, Novartis AG, Teva Pharmaceutical Industries Ltd., AMAG Pharmaceuticals, Akebia Therapeutics, Vifor Pharma Management Ltd, Omeros Corporation, PHARMACOSMOS A/S, Helsinn Healthcare SA, and many others.

Competitive Analysis:

Global folate deficiency anemia drug market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of global folate deficiency anemia drug market for global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Market Definition: Global Folate Deficiency Anemia Drug Market

Folate deficiency anemia is also knowns as Vitamin B9 deficiency anemia. It occurs when lack of lack of vitamin B12 causes the body to produce insufficient or abnormally large red blood cells which ultimately affects the body to be functional. Folate plays an important in the synthesis of genetic material like DNA, RNA and proteins. This deficiency may defacement cell division and an accumulation of possibly toxic metabolites, e.g. homocysteine. It is also important for re regulating the manufacture of red blood cells. It is most commonly found in pregnant and lactating women.

According to the article published in the National Health Services, it is estimated 1 in every 20 people aged 65 to 74 years old and 1 in every 10 people aged 75 or over are living with both vitamin B12 deficiency and folate deficiency anemia. This growing prevalence of folate deficiency anemia worldwide and vulnerable lactating women population are the key factors for the growth of this market.

Market Drivers

  • Prevalence of inflammatory bowel disease worldwide acts as a driver for this market
  • Increase cases of kidney disorders where dialysis is predominant treatment also enhances the market growth
  • Increase in the rate of research and development initiatives is driving folate deficiency anemia therapeutics market
  • Strategic alliance between the companies to increase the availability of the products is also driving the market growth

Market Restraints

  • Inadequate knowledge about folate deficiency anemia in some developing countries acts as a restraint for the market
  • Scientific and major technical challenges for production of disease specific novel therapies is hampering the market growth
  • Patent expiry from many companies and introduction of generic drugs of branded version is expected to limit the growth of the market

For More Insights Get FREE Detailed TOC @

Segmentation: Global Folate Deficiency Anemia Drug Market

By Type

  • Dietary Folate Deficiency Anemia
  • Drug-Induced Folate Deficiency Anemia
  • Unspecified Folate Deficiency Anemia
  • Others

By Treatment Type

  • Medication
  • Dietary Supplements

By Drug Type

  • Vitamin B12 Injections
    • Hydroxocobalamin
    • Cyanocobalamin
  • Iron Deficiency Replacement Drugs
    • Ferric Carboxymaltose
    • Iron Sucrose
    • Iron Polymaltose
    • Folic Acid
    • L-Methylfolate

By Route of Administration

  • Oral
  • Injectable

 By End-Users

    • Hospitals
    • Homecare
    • Specialty Clinics

Key Developments in the Market:

  • In April 2019, Merck KGaA has launched Arcofolin, a monosodium salt of L-5-methyltetrahydrofolic acid for the treatment and prevention from the folate deficiencies. The launch of Arcofolin will give patients a new biologic form of vitamin B9 which is not only easy for the body to metabolize but also enhanced the water solubility and hence improved condition of folate deficiencies
  • In January 2015, Helsinn Healthcare SA In-licensed exclusive U.S. commercialization rights from PHARMACOSMOS A/S for Monofer, an intravenous iron replacement therapy to be developed for the treatment of iron deficiency anaemia. Under the deal terms, PHARMACOSMOS A/S to receive a payments of up to USD 130.00mm for Monofer and eligible to receive further payments for the manufacture and supply of Monofer to Helsinn Healthcare SA in the United States. These strategic alliances between the companies increase availability of the product for patients suffering from folate deficiency anaemia throughout the United States

Reasons to Purchase this Report

  • Current and future of global folate deficiency anemia drug market outlook in the developed and emerging markets
  • The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period
  • Regions/Countries that are expected to witness the fastest growth rates during the forecast period
  • The latest developments, market shares, and strategies that are employed by the major market players

About Data Bridge Market Research Private Ltd:

Data Bridge Market Research Pvt Ltd is a multinational management consulting firm with offices in India and Canada. As an innovative and neoteric market analysis and advisory company with unmatched durability level and advanced approaches. We are committed to uncover the best consumer prospects and to foster useful knowledge for your company to succeed in the market.

Data Bridge Market Research is a result of sheer wisdom and practice that was conceived and built-in Pune in the year 2015. The company came into existence from the healthcare department with far fewer employees intending to cover the whole market while providing the best class analysis. Later, the company widened its departments, as well as expands their reach by opening a new office in Gurugram location in the year 2018, where a team of highly qualified personnel joins hands for the growth of the company. “Even in the tough times of COVID-19 where the Virus slowed down everything around the world, the dedicated Team of Data Bridge Market Research worked round the clock to provide quality and support to our client base, which also tells about the excellence in our sleeve.”

Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe.


Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email @ [email protected]